TERN-501

TERN-501

TERN-501 is an experimental drug currently under development by Terns Pharmaceuticals, a global biopharmaceutical company. TERN-501 is being investigated for its potential use in the treatment of non-alcoholic steatohepatitis (NASH), a chronic liver disease.

Overview

TERN-501 is a thyroid hormone receptor beta (THR-β) agonist. The thyroid hormone receptor is a type of nuclear receptor that is activated by binding thyroid hormone. TERN-501 is designed to selectively target and activate the THR-β in the liver, which is expected to reduce liver fat and inflammation without causing side effects associated with thyroid hormone receptor activation in other tissues.

Clinical Development

The clinical development of TERN-501 is currently in the early stages. Preclinical studies have shown promising results, with TERN-501 demonstrating the ability to reduce liver fat and inflammation in animal models of NASH. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers.

Potential Impact

If successful, TERN-501 could provide a new treatment option for patients with NASH, a disease for which there are currently no approved therapies. NASH is a major cause of cirrhosis and liver failure, and its prevalence is increasing worldwide due to the rising rates of obesity and type 2 diabetes.

See Also

• Non-alcoholic steatohepatitis
• Terns Pharmaceuticals
• Thyroid hormone receptor

‎

‎